Die chronisch-obstruktive Lungenerkrankung (COPD)
详细信息 查看全文
- 作者：A. Klemmer ; T. Greulich ; A. R. Koczulla ; C. F. Vogelmeier
- 关键词：Stadieneinteilung ; Komorbidit盲t ; Krankheitsexazerbation ; Rauchentw枚hnung ; Bronchodilatatoren
- 刊名：CME
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：11
- 期：12
- 页码：52-61
- 全文大小：
- 参考文献：[1]Hogg JC, Chu F, Utokaparch S et al (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645鈥?653PubMed CrossRef
[2]Lamprecht B, McBurnie MA, Vollmer WM et al (2011) COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 139:752鈥?63PubMed Central PubMed CrossRef
[3]Stoller JK, Aboussouan LS (2005) Alpha1-antitrypsin deficiency. Lancet 365:2225鈥?236PubMed CrossRef
[4]Buist AS, McBurnie MA, Vollmer WM et al (2007) International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370:741鈥?50PubMed CrossRef
[5]Jones PW (2009) Health status and the spiral of decline. COPD 6:59鈥?3PubMed CrossRef
[6]Hurst JR, Vestbo J, Anzueto A et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:1128鈥?138PubMed CrossRef
[7]Dodd JW, Hogg L, Nolan J et al (2011) The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 66:425鈥?29PubMed CrossRef
[8]Mentz RJ, Wojdyla D, Fiuzat M et al (2013) Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 111:582鈥?87PubMed CrossRef
[9]Fagerstrom K, Russ C, Yu CR et al (2012) The Fagerstrom Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob Res 14:1467鈥?473PubMed CrossRef
[10]Anderson JE, Jorenby DE, Scott WJ, Fiore MC (2002) Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 121:932鈥?41PubMed CrossRef
[11]Jorenby DE, Leischow SJ, Nides MA et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685鈥?91PubMed CrossRef
[12]Tashkin DP, Rennard S, Hays JT et al (2011) Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 139:591鈥?99PubMed CrossRef
[13]Bullen C, Howe C, Laugesen M et al (2013) Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 382:1629鈥?637PubMed CrossRef
[14]Magnussen H, Waschki B, Watz H (2009) Measurement of physical activity in patients with chronic obstructive pulmonary disease. Med Klin (Munich) 104:303鈥?08CrossRef
[15]Lacasse Y, Goldstein R, Lasserson TJ, Martin S (2006) Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD003793
[16]Gloeckl R, Heinzelmann I, Baeuerle S et al (2012) Effects of whole body vibration in patients with chronic obstructive pulmonary disease 鈥?a randomized controlled trial. Respir Med 106:75鈥?3PubMed CrossRef
[17]Poole PJ, Chacko E, Wood-Baker RW, Cates CJ (2006) Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD002733
[18]Pletz MW (2011) Pneumococcal vaccine: protection of adults and reduction of antibiotic resistence by vaccination of children with a conjugated vaccine. Med Monatsschr Pharm 34:201鈥?05PubMed
[19]Guevara M, Barricarte A, Gil-Setas A et al (2009) Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 15:1013鈥?019PubMed CrossRef
[20]Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Aktualisierte Fassung
[21]Cazzola M, Santangelo G, Piccolo A et al (1994) Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 7:103鈥?07PubMed CrossRef
[22]Kornmann O, Dahl R, Centanni S et al (2011) Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 37:273鈥?79PubMed CrossRef
[23]Martinez FJ, Boscia J, Feldman G et al (2013) Fluticasone furoate/vilanterol (100/25; 200/25 渭g) improves lung function in COPD: a randomised trial. Respir Med 107:550鈥?59PubMed CrossRef
[24]Vogelmeier C, Hederer B, Glaab T et al (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364:1093鈥?103PubMed CrossRef
[25]Singh S, Loke YK, Enright PL, Furberg CD (2011) Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 342:d3215CrossRef
[26]Wise RA, Anzueto A, Cotton D et al (2013) Tiotropium respimat inhaler and the risk of death in COPD. N Engl J Med 369:1491鈥?501PubMed CrossRef
[27]Jones PW, Singh D, Bateman ED et al (2012) Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 40:830鈥?36PubMed CrossRef
[28]Donohue JF, Maleki-Yazdi MR, Kilbride S et al (2013) Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 107:1538鈥?546PubMed CrossRef
[29]Spencer S, Calverley PM, Burge PS, Jones PW (2004) Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 23:698鈥?02PubMed CrossRef
[30]Janson C, Larsson K, Lisspers KH et al (2013) Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting 尾2 agonist: observational matched cohort study (PATHOS). BMJ 346:f3306CrossRef
[31]Nannini LJ, Cates CJ, Lasserson TJ, Poole P (2007) Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD003794
[32]Calverley P, Pauwels R, Vestbo J et al (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361:449鈥?56PubMed CrossRef
[33]Szafranski W, Cukier A, Ramirez A et al (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21:74鈥?1PubMed CrossRef
[34]Dransfield MT, Bourbeau J, Jones PW et al (2013) Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 1:210鈥?23PubMed CrossRef
[35]Wedzicha JA, Decramer M, Ficker JH et al (2013) Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel-group study. Lancet Respir Med 1:199鈥?09PubMed CrossRef
[36]D鈥橴rzo A, Vogelmeier C (2012) Future of chronic obstructive disease management. Expert Rev Respir Med 6:285鈥?99PubMed CrossRef
[37]Wedzicha JA, Rabe KF, Martinez FJ et al (2013) Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 143:1302鈥?311PubMed CrossRef
[38]Wouters EF, Bredenbroker D, Teichmann P et al (2012) Effect of the phosphodiesterase 4 inhibitor rofl umilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab 97:E1720鈥揈1725PubMed CrossRef
[39]Poole P, Black PN, Cates CJ (2012) Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD001287
[40]Zheng JP, Wen FQ, Bai CX et al (2013) High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study. COPD 10:164鈥?71PubMed CrossRef
[41]Leuppi JD, Schuetz P, Bingisser R et al (2013) Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 309:2223鈥?231PubMed CrossRef
[42]Llor C, Moragas A, Hern谩ndez S et al (2012) Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186:716鈥?23PubMed CrossRef
[43]Stockley RA, O鈥橞rien C, Pye A, Hill SL (2009) Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. 2000. Chest 136(5 Suppl):e30
[44]Stolz D, Christ-Crain M, Bingisser R et al (2007) Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitoninguidance with standard therapy. Chest 131:9鈥?9PubMed CrossRef
[45]Sethi S, Murphy TF (2008) Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359:2355鈥?365PubMed CrossRef - 作者单位：A. Klemmer (1)
T. Greulich (1)
A. R. Koczulla (1)
C. F. Vogelmeier (1)
1. Klinik f眉r Innere Medizin mit Schwerpunkt Pneumologie, Universit盲tsklinikum Gie脽en und Marburg, Standort Marburg, Baldingerstr. 1, 35043, Marburg, Deutschland - 刊物类别：General Practice / Family Medicine; Internal Medicine; Primary Care Medicine; Cardiology; Gastroente
- 刊物主题：General Practice / Family Medicine; Internal Medicine; Primary Care Medicine; Cardiology; Gastroenterology; Diabetes;
- 出版者：Springer Berlin Heidelberg
- ISSN：1614-3744
文摘